Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/33707
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSaleem, Ferhan-
dc.contributor.authorRyerson, Christopher J-
dc.contributor.authorSarma, Nandini-
dc.contributor.authorJohannson, Kerri-
dc.contributor.authorMarcoux, Veronica-
dc.contributor.authorFisher, Jolene-
dc.contributor.authorAssayag, Deborah-
dc.contributor.authorManganas, Helene-
dc.contributor.authorKhalil, Nasreen-
dc.contributor.authorMorisset, Julie-
dc.contributor.authorGlaspole, Ian N-
dc.contributor.authorGoh, Nicole S L-
dc.contributor.authorOldham, Justin M-
dc.contributor.authorCox, Gerard-
dc.contributor.authorFell, Charlene-
dc.contributor.authorGershon, Andrea S-
dc.contributor.authorHalayko, Andrew-
dc.contributor.authorHambly, Nathan-
dc.contributor.authorLok, Stacey D-
dc.contributor.authorShapera, Shane-
dc.contributor.authorTo, Teresa-
dc.contributor.authorWilcox, Pearce G-
dc.contributor.authorWong, Alyson W-
dc.contributor.authorKolb, Martin-
dc.contributor.authorKhor, Yet H-
dc.date2023-
dc.date.accessioned2023-09-13T04:43:30Z-
dc.date.available2023-09-13T04:43:30Z-
dc.date.issued2023-12-
dc.identifier.citationAnnals of the American Thoracic Society 2023-12; 20(12)en_US
dc.identifier.issn2325-6621-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/33707-
dc.description.abstractHypoxemia in fibrotic interstitial lung disease (ILD) indicates disease progression and is of prognostic significance. The onset of hypoxemia signifies disease progression and predicts mortality in fibrotic interstitial lung diseases (ILD). Accurately predicting new-onset exertional and resting hypoxemia prompts appropriate patient discussion and timely consideration of home oxygen. We derived and externally validated a risk prediction tool for both new-onset exertional and resting hypoxemia. This study used ILD registries from Canada for the derivation cohort and from Australia and United States for the validation cohort. New-onset exertional and resting hypoxemia were defined as nadir SpO2 <88% during 6-minute walk tests, resting SpO2 <88%, or the initiation of ambulatory or continuous oxygen. Candidate predictors included patient demographics, ILD subtypes, and pulmonary function. Time-varying Cox regression was used to identify the top performing prediction model according to Akaike information criterion and clinical usability. Model performance was assessed using Harrell's C-index and goodness-of-fit (GoF) likelihood ratio test. A categorized risk prediction tool was developed. The best-performing prediction model for both new-onset exertional and resting hypoxemia included age, body mass index, a diagnosis of idiopathic pulmonary fibrosis, and percent-predicted forced vital capacity and diffusing capacity of carbon monoxide. The risk prediction tool exhibited good performance for exertional hypoxemia (C-index=0.70, GoF=0.85) and resting hypoxemia (C-index=0.77, GoF=0.27) in the derivation cohort, with similar performance in the validation cohort except calibration for resting hypoxemia (GoF=0.001). This clinically applicable risk prediction tool predicted new-onset exertional and resting hypoxemia at six months in the derivation cohort and a diverse validation cohort. Suboptimal GoF in the validation cohort likely reflected overestimation of hypoxemia risk and indicated that the model is not flawed due to underestimation of hypoxemia.en_US
dc.language.isoeng-
dc.titlePredicting New-onset Exertional and Resting Hypoxemia in Fibrotic Interstitial Lung Disease.en_US
dc.typeJournal Articleen_US
dc.identifier.journaltitleAnnals of the American Thoracic Societyen_US
dc.identifier.affiliationThe University of British Columbia, 8166, Vancouver, British Columbia, Canada.;St. Martinus University, Willemstad, Curaçaoen_US
dc.identifier.affiliationUniversity of British Columbia, Medicine, Vancouver, British Columbia, Canada.en_US
dc.identifier.affiliationOregon Health & Science University, 6684, Portland, Oregon, United States.en_US
dc.identifier.affiliationUniversity of Calgary, Pulmonary Department, Calgary, Canada.en_US
dc.identifier.affiliationUniversity of Saskatchewan, 7235, Medicine, Saskatoon, Saskatchewan, Canada.en_US
dc.identifier.affiliationMcGill University, Medicine, Montreal, Quebec, Canada.en_US
dc.identifier.affiliationCentre Hospitalier de l'Université de Montréal, Département de Médecine, Montreal, Quebec, Canada.en_US
dc.identifier.affiliationCentre Hospitalier de l'Universite de Montreal, 25443, Montreal, Quebec, Canada.en_US
dc.identifier.affiliationAlfred Hospital, 5390, Department of Respiratory and Sleep Medicine, Melbourne, Victoria, Australia.;Centre of Research Excellence in Pulmonary Fibrosis, Brisbane, Queensland, Australia.en_US
dc.identifier.affiliationRespiratory and Sleep Medicineen_US
dc.identifier.affiliationUniversity of Michigan, 1259, Ann Arbor, Michigan, United States.en_US
dc.identifier.affiliationMcMaster University, 3710, Hamilton, Ontario, Canada.en_US
dc.identifier.affiliationUniversity of Calgary, Division of Respiratory Medicine, Calgary, Canada.en_US
dc.identifier.affiliationSunnybrook Research Institute, 282299, Toronto, Ontario, Canada.;ICES, Toronto, Ontario, Canada.en_US
dc.identifier.affiliationUniversity of Manitoba, 8664, SECTION OF RESPIRATORY DISEASES, Winnipeg, Manitoba, Canada.;University of Manitoba, 8664, Biology of Breathing Group, Children's Hospital Research Institute of Manitoba, Winnipeg, Manitoba, Canada.en_US
dc.identifier.affiliationMcMaster University, Medicine, Hamilton, Ontario, Canada.en_US
dc.identifier.affiliationUniversity of Saskatchewan, 7235, Saskatoon, Canada.en_US
dc.identifier.affiliationUniversity of Toronto, 7938, Toronto, Ontario, Canada.en_US
dc.identifier.affiliationThe Hospital for Sick Children, Child Health Evaluative Sciences, Toronto, Ontario, Canada.en_US
dc.identifier.affiliationSt Paul's Hospital, Vancouver, British Columbia, Canada.en_US
dc.identifier.affiliationUniversity of British Columbia, Department of Medicine, Vancouver, British Columbia, Canada.;St. Paul's Hospital, Centre for Heart Lung Innovation, Vancouver, British Columbia, Canada.en_US
dc.identifier.affiliationMcMaster University, Hamilton, Ontario, Canada.en_US
dc.identifier.affiliationMonash University, Respiratory Research@Alfred, Central Clinical School, Melbourne, Victoria, Australia.;Austin Health, 3805, Heidelberg, Victoria, Australia.en_US
dc.identifier.doi10.1513/AnnalsATS.202303-208OCen_US
dc.type.contentTexten_US
dc.identifier.orcid0000-0001-9262-0538en_US
dc.identifier.orcid0000-0003-4957-8869en_US
dc.identifier.orcid0000-0002-0246-594Xen_US
dc.identifier.orcid0000-0002-7865-4552en_US
dc.identifier.orcid0000-0001-6932-9443en_US
dc.identifier.orcid0000-0003-3837-1467en_US
dc.identifier.orcid0000-0002-5434-9342en_US
dc.identifier.pubmedid37676933-
item.openairetypeJournal Article-
item.cerifentitytypePublications-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.languageiso639-1en-
crisitem.author.deptRespiratory and Sleep Medicine-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptRespiratory and Sleep Medicine-
crisitem.author.deptInstitute for Breathing and Sleep-
crisitem.author.deptMedicine (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

64
checked on Nov 23, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.